Teduglutide (Revestive®)

Teduglutide (Revestive®) was added to the High Tech Arrangement on 1 January 2021. A Managed Access Protocol is in place for teduglutide. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of teduglutide under the High Tech Arrangement.
The prescribing of teduglutide (Revestive®) under the High Tech Arrangement is confined to designated clinicians who have agreed to the terms of the HSE-Managed Access Protocol and have been approved by the HSE-Medicines Management Programme. The clinician must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.

Between January 2021 and December 2023, expenditure on teduglutide was €2.8 million. For more information please visit Data Snapshots and Publications.

A copy of the HSE-Managed Access Protocol for teduglutide (Revestive®) and the application form for individual reimbursement approval can be found in the Related Files section below.